2020
DOI: 10.1111/jsap.13111
|View full text |Cite
|
Sign up to set email alerts
|

Prospective clinical trial of masitinib mesylate treatment for advanced stage III and IV canine malignant melanoma

Abstract: Objective To investigate efficacy of masitinib mesylate for the treatment of advanced malignant melanoma in dogs. Materials and Methods Prospective clinical trial on 17 dogs with stage III and IV malignant melanoma (two digital, one anal and 14 oral mucosal). Only dogs with advanced gross disease for which the owner declined conventional treatment or dogs with progressive tumour despite conventional treatment were included. Results There was a partial response in two dogs, stable disease in seven and tumour pr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
16
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 15 publications
(16 citation statements)
references
References 37 publications
0
16
0
Order By: Relevance
“…The small molecule inhibitors masitinib and toceranib are licensed to treat nonresectable Patnaik grade II or III canine cutaneous mast cell tumours. They have also been reported to be of benefit in other tumour types including melanoma [9], apocrine gland anal sac adenocarcinoma [32], thyroid carcinoma [33] and epitheliotrophic lymphoma [34]. Drug targets are the receptor tyrosine kinase family of transmembrane proteins including stem cell factor receptor (c-kit), platelet derived growth factors (PDGFRs), lymphocyte specific protein kinase (Lck), focal adhesion kinase (Fak) in the case of masitinib [9] and additionally in the case of toceranib: vascular endothelial growth factor receptor (VEGFR), stem cell factor (SCF), colony stimulating factor-1 (CSF-1), glial derived neurotrophic factor (GDNF), and FMS related tyrosine kinase 3 ligand (FLT3L) [35].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The small molecule inhibitors masitinib and toceranib are licensed to treat nonresectable Patnaik grade II or III canine cutaneous mast cell tumours. They have also been reported to be of benefit in other tumour types including melanoma [9], apocrine gland anal sac adenocarcinoma [32], thyroid carcinoma [33] and epitheliotrophic lymphoma [34]. Drug targets are the receptor tyrosine kinase family of transmembrane proteins including stem cell factor receptor (c-kit), platelet derived growth factors (PDGFRs), lymphocyte specific protein kinase (Lck), focal adhesion kinase (Fak) in the case of masitinib [9] and additionally in the case of toceranib: vascular endothelial growth factor receptor (VEGFR), stem cell factor (SCF), colony stimulating factor-1 (CSF-1), glial derived neurotrophic factor (GDNF), and FMS related tyrosine kinase 3 ligand (FLT3L) [35].…”
Section: Discussionmentioning
confidence: 99%
“…Oral melanomas are generally reported to have a poor prognosis, with a metastatic rate of 53-67%, and a reported survival time of only 1 to 4 months without treatment, with most animals euthanised due to either progression of local disease, or evidence of gross metastasis [3,[9][10][11]. Aggressive surgical excision with or without adjunctive radiotherapy has traditionally been regarded as the best approach to treatment of local disease, with survival times following surgery varying widely from 3 to 45 months [9,12,13]. Malignant melanoma is regarded as refractory to chemotherapy [14,15].…”
Section: Introductionmentioning
confidence: 99%
“…Aberrant expression of the oncogene KIT and mutation of platelet derived growth factor receptor, PDGFRA, are more common in mucosal melanoma compared to cutaneous melanoma in people [ 85 ]. In canine oral melanoma, KIT mutation is uncommon and anti-KIT targeted therapy has resulted in only modest results [ 49 , 86 ]. However, PDGFRα/β expression was found in around 50% of oral canine melanoma and α and β co-expression was shown to correlate with a worse prognosis [ 87 ].…”
Section: Canine Oral Melanoma As a Translational Model Of Mucosal Melanoma And Immunotherapy In Peoplementioning
confidence: 99%
“…Copy number increases in Kit have been reported in 26-65% of COMs, either as focal amplifications or part of large chromosomal rearrangements [3,45,60], but these do not necessarily result in increased expression at a protein level [60], and there is no significant correlation between KIT expression and any histopathologic feature, WHO stage, or overall patient survival times [61,62]. A recent clinical trial of TKI masitinib mesylate in 17 patients with advanced COM yielded disappointing results [63], and further trials are required to assess TKI use as adjunctive treatments, particularly for the individual cases where activating mutations are present [3,59,64].…”
Section: Notable Genes Lacking Recurrent Aberrations In Commentioning
confidence: 99%